InfuSystem price target lowered to $12 from $14 at B. Riley

B. Riley lowered the firm’s price target on InfuSystem (INFU) to $12 from $14 and keeps a Buy rating on the shares following the Q1 report. The company remains focused on improving profitability while pursuing growth opportunities such as advanced wound care and chemo mouthpiece, the analyst tells investors in a research note. Riley expects InfuSystem to continue to repurchase shares throughout the year.